$0.721
+0.010 (+1.39%)收盤時
- High
- 0.730
- Open
- 0.661
- VWAP
- 0.69
- Vol
- 188.27K
- Mkt Cap
- 34.34M
- Low
- 0.632
- Amount
- 130.69K
- EV/EBITDA, TTM
- 0.00
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
估值指標
事件時間軸
資訊
8.503-25GlobenewswireRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
3.003-15NASDAQ.COMCYCLO THERAPEUTICS Earnings Preview: Recent $CYTH Insider Trading, Hedge Fund Activity, and More
9.503-13NewsfilterRafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
9.503-13GlobenewswireRafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
7.002-21PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders
CYTH FAQ — answered by Alphio AI
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。